prikaz prve stranice dokumenta Statini
  Preuzmi
PDF 1 MB
Stručni rad - Pregledni rad
Statini
Farmaceutski glasnik, 63 (2007), 5; 315-331. urn:nbn:hr:163:948126
Nigović, Biljana; Fabijanić, Petra; Bačić-Vrca, Vesna

Citirajte ovaj rad

Nigović, B., Fabijanić, P. i Bačić Vrca, V. (2007). Statini. Farmaceutski glasnik, 63. (5), 315-331. Preuzeto s https://urn.nsk.hr/urn:nbn:hr:163:948126

Nigović, Biljana, et al. "Statini." Farmaceutski glasnik, vol. 63, br. 5, 2007, str. 315-331. https://urn.nsk.hr/urn:nbn:hr:163:948126

Nigović, Biljana, Petra Fabijanić i Vesna Bačić Vrca. "Statini." Farmaceutski glasnik 63, br. 5 (2007): 315-331. https://urn.nsk.hr/urn:nbn:hr:163:948126

Nigović, B., Fabijanić, P. i Bačić Vrca, V. (2007) 'Statini', Farmaceutski glasnik, 63(5), str. 315-331. Preuzeto s: https://urn.nsk.hr/urn:nbn:hr:163:948126 (Datum pristupa: 10.12.2024.)

Nigović B, Fabijanić P, Bačić Vrca V. Statini. Farmaceutski glasnik [Internet]. 2007. [pristupljeno 10.12.2024.];63(5):315-331. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:163:948126

B. Nigović, P. Fabijanić i V. Bačić Vrca, "Statini", Farmaceutski glasnik, vol. 63, br. 5, str. 315-331, 2007. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:163:948126. [Citirano: 10.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:163:948126
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (hrvatski)Statini
AutorBiljana Nigović
AutorPetra Fabijanić
AutorVesna Bačić-Vrca
Autorova ustanovaSveučilište u Zagrebu
Farmaceutsko-biokemijski fakultet
(Zavod za analitiku i kontrolu lijekova)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Farmacija
Farmacija
Sažetak (engleski)
Statins represent the most efficient drugs for the treatment of hypercholesterolemia. They competitively inhibit the enzyme HMG-CoA {3-hydroxy-3-methylglutaryl-coenzyme A) reductase, a rate-limiting enzyme, which catalyzes the conversion of hydroxymethylglutarate to mevalonate, an early and rate limiting step in the biosynthesis of cholesterol. The statin class of cholesterol-lowering drugs has been introduced since 1987. Lovastatin is derived from Aspergillus terreus. Whereas simvastatin and pravastatin are produced by semi-synthetic ptocesses, fluvastatin, atorvastatin, pitavastatin and rosuvastatin are completely synthetic compounds. Statins are now among the most frequently prescribed drugs. Although ali statins share a cornrnon rnechanism of action, they differ in terrns of their chernical structures, pharrnacokinetics profiles, and lipid-rnodifying efficacy. Lipid-modifying interventions have been shown to decrease the risk of coronary disease both in patients with hypercholesterolemia and in those with relatively norma! levels of low-density lipoprotein cholesterol. This review surnrnarizes the differences of chemical structures and pharmacokinetic properties of statins and emphasizes their clinically irnportant drug interactions and analytical methods for the determination of statins in biological fluids and pharrnaceutical dosage forms.
Ključne riječi (hrvatski)
Jezikhrvatski
Vrsta publikacijeStručni rad - Pregledni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - domaća recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaFarmaceutski glasnik
Brojčani podacivol. 63, br. 5, str. 315-331
p-ISSN0014-8202
URN:NBNurn:nbn:hr:163:948126
Datum objave publikacije2007
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Zaštićeno autorskim pravom.
Datum i vrijeme pohrane2020-11-20 15:41:52